Get started
CanSino Biologics, Inc. Class HCanSino Biologics, Inc. Class HCanSino Biologics, Inc. Class H

CanSino Biologics, Inc. Class H

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsForecastsSeasonalsETFs

Live chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.51 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0790 EUR
Net income (FY)
‪−51.06 M‬ EUR
Revenue (FY)
‪111.17 M‬ EUR
Shares float
‪70.26 M‬
Beta (1Y)
1.36

Employees


Employees (FY)
‪1.1 K‬
Change (1Y)
−389 −26.04%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About CanSino Biologics, Inc. Class A


Sector
Health Technology
Industry
Biotechnology
CEO
Xue Feng Yu
Website
cansinotech.com
Headquarters
Tianjin
Founded
2009
ISIN
CNE100003F01
FIGI
BBG00NQHDN53
CanSino Biologics, Inc. engages in the research and development, manufacturing, and sale of vaccines. It offers shingles, meningitis, polio, adenovirus, and tuberculosis vaccines. The company was founded by Xuan Liu, Xue Feng Yu, Tao Zhu, Dong Xu Qiu and Hui Hua Mao on January 13, 2009 and is headquartered in Tianjin, China.

Check out other big names from the same industry as CJH.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


513120
GF CSI Hong Kong Brand Name Drug Exchange Traded Fund Units
Weight
0.42%
Market value
‪7.96 M‬
USD
FEMS
First Trust Emerging Markets Small Cap AlphaDEX Fund
Weight
0.32%
Market value
‪838.71 K‬
USD
513780
INVESCO Great Wall CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units
Weight
0.43%
Market value
‪655.88 K‬
USD
FLXC
Franklin FTSE China UCITS ETF USD
Weight
0.02%
Market value
‪353.94 K‬
USD
ECNS
iShares MSCI China Small-Cap ETF
Weight
0.31%
Market value
‪337.00 K‬
USD
520700
Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units
Weight
0.41%
Market value
‪294.62 K‬
USD
SPYX
SPDR MSCI Emerging Markets Small Cap UCITS ETF
Weight
0.04%
Market value
‪158.34 K‬
USD
3443
CSOP FTSE Hong Kong Equity ETF
Weight
0.02%
Market value
‪80.67 K‬
USD
GXC
SPDR S&P China ETF
Weight
0.01%
Market value
‪54.41 K‬
USD
FLCH
Franklin FTSE China ETF
Weight
0.02%
Market value
‪40.22 K‬
USD
ISFE
iShares MSCI AC Far East ex-Japan SmallCap UCITS ETF USD
Weight
0.06%
Market value
‪33.12 K‬
USD

Explore more ETFs 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange CanSino Biologics, Inc. Class H stocks are traded under the ticker CJH.
We've gathered analysts' opinions on CanSino Biologics, Inc. Class H future price: according to them, CJH price has a max estimate of 7.27 EUR and a min estimate of 6.13 EUR. Watch CJH chart and read a more detailed CanSino Biologics, Inc. Class H stock forecast: see what analysts think of CanSino Biologics, Inc. Class H and suggest that you do with its stocks.
CJH reached its all-time high on Feb 17, 2021 with the price of 46.6000 EUR, and its all-time low was 1.7985 EUR and was reached on Feb 5, 2024. View more price dynamics on CJH chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track CanSino Biologics, Inc. Class H financials in yearly and quarterly reports right on TradingView.
CanSino Biologics, Inc. Class H is going to release the next earnings report on Oct 28, 2025. Keep track of upcoming events with our Earnings Calendar.
CJH earnings for the last quarter are 0.00 EUR per share, whereas the estimation was −0.01 EUR resulting in a 92.28% surprise. The estimated earnings for the next quarter are 0.00 EUR per share. See more details about CanSino Biologics, Inc. Class H earnings.
CanSino Biologics, Inc. Class H revenue for the last quarter amounts to ‪28.08 M‬ EUR, despite the estimated figure of ‪29.74 M‬ EUR. In the next quarter, revenue is expected to reach ‪35.21 M‬ EUR.
CJH net income for the last quarter is ‪−226.31 K‬ EUR, while the quarter before that showed ‪−1.47 M‬ EUR of net income which accounts for 84.56% change. Track more CanSino Biologics, Inc. Class H financial stats to get the full picture.
As of Oct 17, 2025, the company has ‪1.1 K‬ employees. See our rating of the largest employees — is CanSino Biologics, Inc. Class H on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CanSino Biologics, Inc. Class H EBITDA is ‪−12.75 M‬ EUR, and current EBITDA margin is −24.31%. See more stats in CanSino Biologics, Inc. Class H financial statements.
Like other stocks, CJH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CanSino Biologics, Inc. Class H stock right from TradingView charts — choose your broker and connect to your account.